NZ756069A - Jak1 selective inhibitors - Google Patents
Jak1 selective inhibitorsInfo
- Publication number
- NZ756069A NZ756069A NZ756069A NZ75606918A NZ756069A NZ 756069 A NZ756069 A NZ 756069A NZ 756069 A NZ756069 A NZ 756069A NZ 75606918 A NZ75606918 A NZ 75606918A NZ 756069 A NZ756069 A NZ 756069A
- Authority
- NZ
- New Zealand
- Prior art keywords
- fluoro
- methylsulfonyl
- phenyl
- amino
- indolyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.
Claims (20)
1. A compound of Formula (I): wherein: 10 R1, R3, and R4 are each individually chosen from hydrogen and ; R2 is chosen from hydrogen, methyl, and -CH2CH2OH; n is 1 or 2; R5 is chosen from methyl, ethyl, and 8; R6 is chosen from methyl, chlorine, and fluorine; 15 R7 is selected from methyl, ethyl, and cyclopropyl; and R8 is selected from methyl, ethyl, and ; or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein each of R1-R4 is chosen independently from 20 hydrogen and methyl.
3. The compound of claims 1-2, wherein R1, R3, and R4 are all hydrogen.
4. The compound of claims 1-3, wherein R2 is methyl.
5. The compound of claim 1, wherein R5 is methyl or –CH2OR8.
6. The nd of claims 1-5, wherein R8 is methyl. 30
7. The compound of claim 1, wherein R6 is a methyl or a fluorine atom. 5
8. The compound of claims 1-7, wherein R6 is a fluorine atom.
9. The compound of claim 1, wherein R7 is methyl.
10. The nd of claim 1, having the structure of formula (Ia): Formula (Ia) wherein: R1a, R3a, and R4a are each dually chosen from hydrogen and methyl; R2a is chosen from hydrogen, methyl, and -CH2CH2OH; 15 n is 1 or 2; R5a is chosen from methyl, ethyl, and –CH2OR8a; R6a is chosen from methyl, chlorine, and fluorine; R7a is ed from methyl, ethyl, and cyclopropyl; and R8a is selected from methyl, ethyl and benzyl; 20 or a pharmaceutically acceptable salt thereof. 5
11. The compound of claim 1, having the ure of formula (Ib): Formula (Ib) wherein: R5b is chosen from methyl, ethyl, and –CH2OR8b; 10 R6b is chosen from methyl, chlorine, and fluorine; R7b is ed from methyl, ethyl, and cyclopropyl; and R8b is selected from methyl, ethyl and benzyl; or a pharmaceutically acceptable salt thereof. 15
12. The nd of claim 1, chosen from: (R)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- indolyl)(4-(2-hydroxyethyl)piperazinyl)propanamide; (R)-N-(3-(2-(2-fluoro(methylsulfonyl)phenylamino)methylpyrimidinyl)-1H- indolyl)(4-methylpiperazinyl)propanamide; 20 (R)-N-(3-(2-(3-(ethylsulfonyl)fluorophenylamino)methylpyrimidinyl)-1H- indolyl)(4-methylpiperazinyl)propanamide; (R)-N-(3-(2-(3-(cyclopropylsulfonyl)fluorophenylamino)methylpyrimidinyl)- 1H-indolyl)(4-methylpiperazinyl)propanamide; (R)-N-(3-(5-chloro((2-fluoro(methylsulfonyl)phenyl)amino)pyrimidinyl)-1H- 25 indolyl)(4-methylpiperazinyl)propanamide; (S)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- indolyl)(4-methylpiperazinyl)propanamide; (R)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- indolyl)((3S,5S)-3,4,5-trimethylpiperazinyl)propanamide; 5 (R)-N-(3-(5-fluoro((2-fluoro(methylsulfonyl)phenyl)amino)pyrimidinyl)-1H- 7-yl)((3S,5S)-3,4,5-trimethylpiperazinyl)propanamide; (R)((3S,5S)-3,5-dimethylpiperazinyl)-N-(3-(2-((2-fluoro (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indol yl)propanamide; 10 (S)((3S,5S)-3,5-dimethylpiperazinyl)-N-(3-(2-((2-fluoro (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indol yl)propanamide; (R)((3S,5S)-3,5-dimethylpiperazinyl)-N-(3-(5-fluoro((2-fluoro (methylsulfonyl)phenyl)amino)pyrimidinyl)-1H-indolyl)propanamide; 15 (S)((3S,5S)-3,5-dimethylpiperazinyl)-N-(3-(5-fluoro((2-fluoro (methylsulfonyl)phenyl)amino)pyrimidinyl)-1H-indolyl)propanamide; (S)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- indolyl)(4-methylpiperazinyl)butanamide; (R)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- 20 indolyl)(4-methylpiperazinyl)butanamide; (S)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- 7-yl)methoxy(4-methylpiperazinyl)propanamide; (R)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- indolyl)methoxy(4-methylpiperazinyl)propanamide; 25 (R)-N-(3-(5-fluoro((2-fluoro(methylsulfonyl)phenyl)amino)pyrimidinyl)-1H- indolyl)(4-methyl-1,4-diazepanyl)butanamide; (S)-N-(3-(5-fluoro((2-fluoro(methylsulfonyl)phenyl)amino)pyrimidinyl)-1H- indolyl)(4-methyl-1,4-diazepanyl)butanamide; (S)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- 30 indolyl)((3S,5S)-3,4,5-trimethylpiperazinyl)butanamide; (R)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- indolyl)((3S,5S)-3,4,5-trimethylpiperazinyl)butanamide; (S)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- indolyl)methoxy((3S,5S)-3,4,5-trimethylpiperazinyl)propanamide; 35 (3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- indolyl)methoxy((3S,5S)-3,4,5-trimethylpiperazinyl)propanamide; (S)-N-(3-(5-fluoro(2-fluoro(methylsulfonyl)phenylamino)pyrimidinyl)-1H- indolyl)((3S,5S)-3,4,5-trimethylpiperazinyl)butanamide; 5 (R)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- indolyl)(piperazinyl)propanamide; (S)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- indolyl)(piperazinyl)propanamide; (R)((3R,5R)-3,5-dimethylpiperazinyl)-N-(3-(2-((2-fluoro 10 (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indol yl)butanamide; (S)((3R,5R)-3,5-dimethylpiperazinyl)-N-(3-(2-((2-fluoro (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indol yl)butanamide; 15 (S)((3R,5R)-3,5-dimethylpiperazinyl)-N-(3-(2-((2-fluoro (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indolyl) methoxypropanamide; (R)((3R,5R)-3,5-dimethylpiperazinyl)-N-(3-(2-((2-fluoro lsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indolyl) 20 methoxypropanamide; (S)((3R,5R)-3,5-dimethylpiperazinyl)-N-(3-(5-fluoro((2-fluoro (methylsulfonyl)phenyl)amino)pyrimidinyl)-1H-indolyl)butanamide; (R)((3R,5R)-3,5-dimethylpiperazinyl)-N-(3-(5-fluoro((2-fluoro (methylsulfonyl)phenyl)amino)pyrimidinyl)-1H-indolyl)butanamide; 25 ((3R,5R)-3,5-dimethylpiperazinyl)-N-(3-(5-fluoro((2-fluoro (methylsulfonyl)phenyl)amino)pyrimidinyl)-1H-indolyl) methoxypropanamide; (R)((3R,5R)-3,5-dimethylpiperazinyl)-N-(3-(5-fluoro((2-fluoro (methylsulfonyl)phenyl)amino)pyrimidinyl)-1H-indolyl) 30 methoxypropanamide; (S)-N-(3-(5-fluoro(2-fluoro(methylsulfonyl)phenylamino)pyrimidinyl)-1H- indolyl)methoxy(4-methylpiperazinyl)propanamide; (R)-N-(3-(5-fluoro(2-fluoro(methylsulfonyl)phenylamino)pyrimidinyl)-1H- indolyl)methoxy(4-methylpiperazinyl)propanamide; 35 (S)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- 7-yl)(4-methyl-1,4-diazepanyl)butanamide; (R)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- indolyl)(4-methyl-1,4-diazepanyl)butanamide; 5 (R)-N-(3-(5-fluoro((2-fluoro(methylsulfonyl)phenyl)amino)pyrimidinyl)-1H- indolyl)(4-methylpiperazinyl)butanamide; (S)-N-(3-(5-fluoro((2-fluoro(methylsulfonyl)phenyl)amino)pyrimidinyl)-1H- indolyl)(4-methylpiperazinyl)butanamide; (S)-N-(3-(5-fluoro((2-fluoro(methylsulfonyl)phenyl)amino)pyrimidinyl)-1H- 10 indolyl)methoxy((3S,5S)-3,4,5-trimethylpiperazinyl)propanamide; (R)-N-(3-(5-fluoro((2-fluoro(methylsulfonyl)phenyl)amino)pyrimidinyl)-1H- indolyl)methoxy((3S,5S)-3,4,5-trimethylpiperazinyl)propanamide; (R)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- indolyl)methoxy(4-methyl-1,4-diazepanyl)propanamide; 15 (S)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H- indolyl)methoxy(4-methyl-1,4-diazepanyl)propanamide; (3-(5-fluoro((2-fluoro(methylsulfonyl)phenyl)amino)pyrimidinyl)-1H- indolyl)methoxy(4-methyl-1,4-diazepanyl)propanamide; (R)-N-(3-(5-fluoro((2-fluoro(methylsulfonyl)phenyl)amino)pyrimidinyl)-1H- 20 7-yl)methoxy(4-methyl-1,4-diazepanyl)propanamide; (R)-N-(3-(5-fluoro((2-fluoro(methylsulfonyl)phenyl)amino)pyrimidinyl)-1H- indolyl)(4-methyl-1,4-diazepanyl)propanamide; (S)((R)-2,4-dimethylpiperazinyl)-N-(3-(2-((2-fluoro (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indol 25 yl)propanamide; (R)((R)-2,4-dimethylpiperazinyl)-N-(3-(2-((2-fluoro (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indol yl)propanamide; (R)((R)-2,4-dimethylpiperazinyl)-N-(3-(5-fluoro((2-fluoro 30 (methylsulfonyl)phenyl)amino)pyrimidinyl)-1H-indolyl)propanamide; (S)((R)-2,4-dimethylpiperazinyl)-N-(3-(2-((2-fluoro (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indol yl)butanamide; (R)((R)-2,4-dimethylpiperazinyl)-N-(3-(2-((2-fluoro 35 (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indol yl)butanamide; (S)((R)-2,4-dimethylpiperazinyl)-N-(3-(5-fluoro((2-fluoro (methylsulfonyl)phenyl)amino)pyrimidinyl)-1H-indolyl)butanamide; 5 (R)((R)-2,4-dimethylpiperazinyl)-N-(3-(5-fluoro((2-fluoro (methylsulfonyl)phenyl)amino)pyrimidinyl)-1H-indolyl)butanamide; (S)((R)-2,4-dimethylpiperazinyl)-N-(3-(2-((2-fluoro (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indolyl) methoxypropanamide; 10 (R)((R)-2,4-dimethylpiperazinyl)-N-(3-(2-((2-fluoro (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indolyl) methoxypropanamide; (S)((R)-2,4-dimethylpiperazinyl)-N-(3-(5-fluoro((2-fluoro (methylsulfonyl)phenyl)amino)pyrimidinyl)-1H-indolyl) 15 methoxypropanamide; (R)((R)-2,4-dimethylpiperazinyl)-N-(3-(5-fluoro((2-fluoro lsulfonyl)phenyl)amino)pyrimidinyl)-1H-indolyl) methoxypropanamide; (R)((S)-2,4-dimethylpiperazinyl)-N-(3-(2-((2-fluoro 20 (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indol panamide; (S)((S)-2,4-dimethylpiperazinyl)-N-(3-(2-((2-fluoro (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indol yl)propanamide; 25 (R)((S)-2,4-dimethylpiperazinyl)-N-(3-(2-((2-fluoro (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indol yl)butanamide; (S)((S)-2,4-dimethylpiperazinyl)-N-(3-(2-((2-fluoro (methylsulfonyl)phenyl)amino)methylpyrimidinyl)-1H-indol 30 yl)butanamide; (R)ethoxy-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino)methylpyrimidin- 4-yl)-1H-indolyl)(4-methylpiperazinyl)propanamide; (R)ethoxy-N-(3-(5-fluoro((2-fluoro(methylsulfonyl)phenyl)amino)pyrimidin- 4-yl)-1H-indolyl)(4-methylpiperazinyl)propanamide; 35 (R)(benzyloxy)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino) pyrimidinyl)-1H-indolyl)(4-methylpiperazinyl)propanamide; (S)(benzyloxy)-N-(3-(2-((2-fluoro(methylsulfonyl)phenyl)amino) methylpyrimidinyl)-1H-indolyl)(4-methylpiperazinyl)propanamide; 5 (R)-N-(3-(5-fluoro(2-fluoro(methylsulfonyl)phenylamino)pyrimidinyl)-1H- indolyl)methoxy(piperazinyl)propanamide; (S)-N-(3-(5-fluoro(2-fluoro(methylsulfonyl)phenylamino)pyrimidinyl)-1H- indolyl)methoxy(piperazinyl)propanamide; or a pharmaceutically acceptable salt thereof.
13. The compound of claim 1, which is (R)-N-(3-(5-fluoro(2-fluoro (methylsulfonyl)phenylamino)pyrimidinyl)-1H-indolyl)methoxy(4- methylpiperazinyl)propanamide, or a pharmaceutically acceptable salt thereof. 15
14. The nd of claim 1, which is (R)-N-(3-(5-fluoro(2-fluoro (methylsulfonyl)phenylamino)pyrimidinyl)-1H-indolyl)methoxy(4- methylpiperazinyl)propanamide.
15. The compound of claim 1, which is a pharmaceutically acceptable salt of (R)-N-(3- 20 oro(2-fluoro(methylsulfonyl)phenylamino)pyrimidinyl)-1H-indol yl)methoxy(4-methylpiperazinyl)propanamide.
16. A pharmaceutical ition comprising a compound according to claims 1-15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable 25 diluent, excipient, or carrier.
17. Use of a compound according to claims 1-15, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a JAK1-related disorder, wherein the JAK1-related disorder is chosen from type 1 diabetes, lupus, multiple 30 sclerosis, rheumatoid tis, psoriasis, asthma, atopic dermatitis, autoimmune d disorders, ulcerative colitis, Crohn’s disease, COPD, vitiligo, and ia areata.
18. Use of a pharmaceutical composition comprising a compound of any one of claims 35 1-15, or a pharmaceutically acceptable salt thereof, in the cture of a medicament for treating a JAK1-related disorder, wherein the JAK1-related disorder is chosen from Type 1 diabetes, lupus, multiple sis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn’s disease, COPD, go, and ia areata.
19. Use according to claims 17 or claim 18, wherein the JAK1-related disorder is asthma.
20. Use ing to claims 17 or claim 18, wherein the JAK1-related disorder is 10 COPD. Counts 22500 10000 10 20 30 40 50 Position [°2?] (Copper (Cu)) E o s in o p h ils in B A L p < 0 .0 0 1 n .s . n .s . p < 0 .0 1 p < 0 .0 1 p < 0 .0 0 1 3 7 % 2 8 % 6 8 % 6 1 % 9 7 % 10 (x G ro u p 1 G ro u p 2 G ro u p 3 G ro u p 4 G ro u p 5 G ro u p 6 G ro u p 7 G ro u p 8 0 .0 8 ? g /k g 0 .1 1 ? g /k g 0 .6 ? g /k g 4 .8 ? g /k g B u d e s o n id e 3 0 0 ? g /k g x 2 201817_200572_WO_PCT_SEQLTXT-1(5918171.1).txt
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447057P | 2017-01-17 | 2017-01-17 | |
| PCT/EP2018/051038 WO2018134213A1 (en) | 2017-01-17 | 2018-01-16 | Jak1 selective inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ756069A true NZ756069A (en) | 2025-08-29 |
| NZ756069B2 NZ756069B2 (en) | 2025-12-02 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230069T1 (en) | Jak1 selective inhibitors | |
| AU2018413791B2 (en) | Aminopyrimidine derivatives as CTPS1 inhibitors | |
| RU2405780C2 (en) | Chemical compounds | |
| JP6118383B2 (en) | Tricyclic pyrrolo derivatives, their preparation and their use as kinase inhibitors | |
| MX2022007842A (en) | Substituted bicyclic piperidine derivatives useful as t cell activators. | |
| IL275762B2 (en) | Derivatives of phenyl-so2-nh-c(=o)-phenyl-piperazine-ch2-1,2-cyclohexane-bicyclo[1.1.1]pentane and pharmaceutical compositions comprising them | |
| CA2682329A1 (en) | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | |
| EP3484887A1 (en) | Wee-1 inhibiting pyrazolopyrimidinone compounds | |
| HRP20170456T1 (en) | NEW CONDENSED PYRIMIDINE DERIVATIVES INTENDED TO INHIBIT THE ACTIVITY OF TYROSINE KINASE | |
| CN114746414B (en) | Aza-quinoline compounds and uses thereof | |
| JP2011507854A5 (en) | ||
| NZ629432A (en) | Heterocyclyl compounds as mek inhibitors | |
| GEP20156282B (en) | Compounds and compositions as protein kinase inhibitors | |
| TN2013000394A1 (en) | PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN-RELATED KINASES | |
| WO2019130230A1 (en) | Heterocyclic amides as kinase inhibitors | |
| PE20151249A1 (en) | PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF JAK KINASES | |
| BRPI0410720A (en) | quinazolines and pyrido [3,4-d] pyrimidines as tyrosine kinase receptor inhibitors | |
| US20230020663A1 (en) | Sulfonamide inhibitors as ctps1 inhibitors | |
| HRP20192197T2 (en) | CARBAZOLE DERIVATIVES | |
| HRP20170119T1 (en) | Novel pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt (pkb) phosphorylation inhibitors | |
| RU2007134105A (en) | 4-OXOCHINAZOLIN-3-IL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | |
| Simov et al. | Structure-based design and development of (benz) imidazole pyridones as JAK1-selective kinase inhibitors | |
| WO2015091584A1 (en) | Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors | |
| JP2016540803A5 (en) | ||
| FI3604304T3 (en) | Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JAN 2027 BY ANAQUA SERVICES Effective date: 20251217 |